When Proteins Act as "Smart Carriers": What Is the Future of Localized Drug Administration

You blink after putting in a drop of eye drops—an action you have likely performed countless times. The liquid contacts the eye, bringing a brief sensation of coolness, and then you move on, without giving it another thought.

But the moment that droplet touches the cornea, a millennia-long revolution in drug delivery unfolds right before your eyes. Less than 5% of the instilled solution actually penetrates the inner eye to exert therapeutic effects. The remaining 95% gets washed away by tear fluid within seconds of blinking or blocked by the corneal barrier. Biologics, including antibodies, peptides and recombinant proteins, face an even greater hurdle: their molecular weights often reach tens of thousands of daltons. The tight junctions of the corneal epithelium severely restrict paracellular transport, while transcellular transport remains extremely inefficient. The eye, one of the human body’s most structurally intricate organs with complex physiological barriers, is equipped with sophisticated protective defenses, rendering it an extremely challenging target for localized drug administration.

This is precisely what makes localized drug therapy so fascinating: deceptively simple on the surface, yet remarkably intricate beneath.

Protein Nanocage for Precision Transmembrane Delivery

I. From Medicinal Plasters to Protein-Based Delivery Carriers: A Millennia-Long Pursuit of Precision Therapeutic Delivery

The core principle of direct administration of therapeutics to lesion sites has long served as a cornerstone of medical practice across civilizations. Dating back to ancient Egyptian herbal poultices and traditional Chinese medicinal plasters, localized delivery technologies advanced steadily after the FDA’s approval of the first transdermal patch in the 1980s. The commercial success of transdermal patches validated a fundamental proposition: drugs do not necessarily require entry into systemic circulation to produce therapeutic benefits. Localized, precise controlled release at target lesions often delivers safer and more efficient treatment outcomes.

However, the rise of biologics in the 21st century brought unprecedented challenges. These macromolecular therapeutics feature high molecular weights, complex spatial conformations and low ex vivo structural stability, making them poorly compatible with delivery systems engineered for conventional small-molecule therapeutics. Against this backdrop, researchers shifted focus to biologically derived protein biomaterials: proteins can function not only as therapeutic payloads but also as custom-engineered intelligent delivery carriers.

II. Protein Carriers: Reshaping the Technological Landscape of Localized Drug Therapy

Proteins possess dual functionality: they act as therapeutic drugs as well as customizable delivery vehicles.

Mussel adhesive protein (MAP)-based adhesive nanoparticles serve as a representative case. According to a 2025 study published in ACS Biomaterials Science & Engineering, researchers modified mussel adhesive proteins via bioengineering and chemical functionalization to fabricate nanoparticles with robust tissue adhesion capacity. These nanoparticles firmly anchor to tissue surfaces, enabling sustained local drug retention and prolonged release, and effectively resolve the drug washout limitation common to traditional localized delivery systems. The research confirmed that MAP-based adhesive nanoparticles hold promising applications in oncology and regenerative medicine.

Engineered protein nanoparticles offer an innovative strategy for localized arthritis treatment. A 2026 research report documented that self-assembled engineered protein K72 was utilized to build a nano-delivery system encapsulating the JAK inhibitor upadacitinib. The formulation enabled sustained drug release and superior tissue permeability. Upon topical administration, it precisely targets inflamed articular tissue, suppresses rheumatoid arthritis progression, and exhibits undetectable systemic toxicity in animal models.

Sprayable MAP-derived adhesive microgels address unmet clinical needs in transplant immunosuppression. Researchers constructed a sprayable adhesive microgel platform from bioengineered mussel adhesive proteins for localized delivery of immunosuppressive agents. The microgel tightly adheres to graft surfaces, maintaining high drug concentrations at transplant sites while eliminating systemic side effects associated with systemic immunosuppressive regimens.

All these examples point to one clear trend: proteins are evolving from delivered therapeutics to delivery-enabling biomaterials. To develop high-performance, target-specific protein delivery vehicles, rational protein engineering design stands as the core determinant.

III. AI-Powered Protein Design: Enabling On-Demand Customization of Localized Drug Delivery Carriers

AI Reverse Design Function to Protein Structure

Conventional protein engineering relies heavily on structural biological data and iterative screening via site-directed mutagenesis, a workflow plagued by lengthy R&D cycles and low hit rates. For a protein consisting of 100 amino acids, single amino acid substitution generates around 1,900 unique variants; double substitutions yield nearly 2 million candidate sequences. Searching for optimal candidates within this vast sequence space is essentially a needle-in-a-haystack endeavor.

The maturation of AI-driven protein design tools is fundamentally overhauling this classic R&D paradigm. Conventional development adopts a forward verification pipeline: gene sequence → protein folded conformation → biological function.

MatwingsVenus™ adopts inverse design logic. It takes predefined functional demands—such as prolonged corneal adhesion, cartilage permeability, or high soluble expression yield—as input constraints. Its underlying foundation model rapidly predicts the protein conformations required to meet target functional criteria and back-engineers optimal amino acid sequences, drastically cutting down repeated trial-and-error lab work.

This "function-first, sequence-later" inverse design framework delivers critical support for the tailor-made development of localized drug delivery carriers:

Design of adhesive proteins

To enhance MAP affinity for specific tissue surfaces (cornea, articular cartilage, tumor tissue, etc.), AI starts directly from the functional requirement of durable retention on designated tissue and generates novel optimized protein sequences.

Optimization of protein nanoparticle self-assembly

The stability, drug loading capacity and release kinetics of engineered protein nanoparticles depend entirely on protein folding and self-assembly behaviors. AI predicts and fine-tunes these properties at the sequence level, bypassing time-consuming "synthesis → testing → failure" cycles inherent to traditional R&D workflows.

Improved manufacturability of protein delivery carriers

Industrial translation of localized delivery carriers demands high-titer soluble protein expression in microbial hosts such as E. coli. Equipped with AI-directed evolution algorithms, the Xiaoque Platform optimizes expression characteristics directionally while preserving core protein functions, compressing multi-year R&D schedules into several months.

In April 2026, Matwings Technology rolled out MatwingsVenus™, a conversational intelligent agent platform dedicated to protein R&D. Centered on an intelligent agent framework, it delivers a full-suite one-stop solution for protein research and development. Users only need to state R&D goals in natural language; the system automatically decomposes complex tasks and coordinates integrated modules for design, prediction, data analysis and high-throughput screening. Its application scope covers fundamental research, enzyme mining, directed evolution, de novo protein design, and automated wet-lab collaboration.

The platform integrates more than 200 specialized protein design tools, resources verified by over 50 in-house experts, and over 30 functional modules calibrated by domain specialists. Most importantly, it establishes a conversational dry-wet experimental closed loop: after AI finishes sequence design, the platform automatically connects with automated lab systems and guides robotic equipment to execute core experimental workflows, including sample preparation, protein purification and functional biological assays.

For instance, researchers developing adhesive protein carriers for ocular surface therapy can simply input natural language functional requirements, such as "Design a protein carrier that stably adheres to corneal surfaces for more than 8 hours under continuous tear fluid flushing". The platform autonomously completes the full pipeline spanning sequence design through laboratory validation.

IV. The Industrial Logic Underpinning Localized Drug Therapy

Micro Molecules, Macro Industry

The commercial value of localized drug administration has been fully validated by market performance. Market research indicates the global localized drug delivery market exceeded hundreds of billions of US dollars in 2025. Biologics represented by monoclonal antibodies see rapidly expanding clinical adoption in localized therapy, with core indications covering age-related macular degeneration, osteoarthritis and solid tumors.

Two core competitive advantages fuel this robust market growth:

First, enhanced drug safety profiles. Systemic administration distributes therapeutic agents across the entire body via blood circulation. TNF-α inhibitors for rheumatoid arthritis elevate infection risks, while immune checkpoint inhibitors for oncology may trigger systemic immune-related adverse events. Localized delivery concentrates therapeutics exclusively at lesion sites and avoids exposure of healthy organs. Studies on topically administered engineered protein nanoparticles for arthritis confirm zero detectable systemic toxicity, strongly validating this safety advantage.

Second, superior therapeutic potency. Systemically administered drugs undergo dilution, metabolic degradation and renal clearance before reaching target lesions. Localized delivery delivers therapeutics directly to diseased tissue, generating stronger curative effects at lower dosages. Inhaled protein therapeutics act directly on airway mucosa; intra-articular injected protein formulations target synovial tissue precisely. Precision administration translates to amplified therapeutic potency.

Protein-based delivery carriers mark the next major breakthrough in localized drug administration, featuring inherent biocompatibility, tunable engineering properties and multifunctional versatility. Via rational protein engineering, these biomaterials can be tailored into tissue adhesives, permeability enhancers, sustained-release depots and targeting ligands, covering nearly all functional demands of localized therapy. The maturation of AI-powered protein design technologies has turned the customized development of these multifunctional protein carriers from theoretical concept into industrial reality.

V. Revisiting That Single Drop of Eye Drops

The next time you instill eye drops, pause to reflect on the millennia of innovation behind that tiny droplet.

Its development traces back to ancient herbal poultices, advanced via transdermal patch technology, and is now being revolutionized by protein nanocarriers. It overcomes biological barriers shaped by hundreds of millions of years of evolutionary adaptation, unlocking transformative therapeutic breakthroughs enabled by precision protein engineering.

The core essence of localized drug delivery lies in achieving optimized, site-specific therapy: delivering the exact required dosage, acting solely on lesion sites and producing only intended therapeutic effects. Protein biomaterials have emerged as an ideal platform to realize this precise therapeutic paradigm. Whether MAP-derived nanocarriers or self-assembled engineered protein targeted delivery systems, all rely on one foundational capability: precise regulation of the protein "sequence → conformation → function" relationship.

This constitutes the core value of AI-powered protein design platforms. Researchers are no longer limited to random screening of natural protein libraries; instead, algorithms can directly generate optimal carrier sequences based on predefined functional demands.

From ancient Egyptian herbal poultices to modern engineered protein nanocarriers; from scopolamine transdermal patches applied to skin to protein carrier eye drops capable of crossing the corneal barrier—humanity has spent thousands of years perfecting the seemingly simple goal of delivering drugs exactly where treatment is needed. Deep integration between protein engineering and artificial intelligence now makes this therapeutic vision more precise, efficient and broadly accessible than ever before.